Education
About Us
Working with TipRanks
Follow Us
MedAdvisor Limited (AU:AHE)
ASX:AHE
AHE Stock Chart & Stats
AU$0.02
<AU$0.01(4.76%)
―
--
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.17
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.73M
Market Cap
AU$14.01M
Enterprise ValueAU$17.00M
Total Cash (Recent Filing)AU$10.30M
Total Debt (Recent Filing)AU$17.40M
Price to Earnings (P/E)―
Beta1.91
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding636,978,100
10 Day Avg. Volume474,818
30 Day Avg. Volume1,728,714
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)11.59
Price to Sales (P/S)0.19
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$110.67M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue ModelMedAdvisor's business earns revenue from pharmacy software subscriptions and paid life-sciences programs, creating recurring and contractable revenue streams. This model supports predictable cash inflows as network scale grows, enabling multi-year customer relationships and program renewals that bolster long-term revenue stability.
Improving Free Cash FlowAn 18.49% increase in free cash flow indicates improving cash generation versus prior periods. Sustained FCF growth provides the company with more internal funding capacity for product development, platform investment or working capital, reducing near-term reliance on external financing if the trend continues over the medium term.
Platform Connecting Pharmacies, Brands, ConsumersThe platform model linking pharmacies, brands and consumers creates network effects and a differentiated distribution channel for brand-sponsored programs. That structural position makes MedAdvisor valuable to pharma clients and supports cross-selling, higher program volumes and potential scale advantages as the pharmacy network expands.
Bears Say
Sharp Revenue Decline And Weak ProfitabilityA ~39% revenue drop combined with deeply negative margins shows structural demand or execution issues. Prolonged top-line contraction and persistent losses impair the company's ability to cover fixed costs, erode pricing leverage, and limit resources for R&D or sales investment needed to rebuild sustainable profitability.
Negative Equity And Elevated Solvency RiskNegative shareholders' equity and a distorted debt-to-equity ratio reflect accumulated losses and capital depletion. This structural weakness reduces financial flexibility, can hinder access to capital markets, and increases refinancing or covenant risk, constraining strategic options until equity is rebuilt or profitability restored.
Core Operations Not Yet Cash-flow PositiveDespite rising free cash flow, negative operating cash flow signals core operations fail to generate sustainable cash. Continued operational cash deficits require external financing or cost cutting to cover ongoing expenses, creating execution risk and pressure on long-term viability absent a clear revenue recovery path.
MedAdvisor Limited News
AHE FAQ
What was MedAdvisor Limited’s price range in the past 12 months?
MedAdvisor Limited lowest share price was AU$0.02 and its highest was AU$0.17 in the past 12 months.
What is MedAdvisor Limited’s market cap?
MedAdvisor Limited’s market cap is AU$14.01M.
When is MedAdvisor Limited’s upcoming earnings report date?
MedAdvisor Limited’s upcoming earnings report date is Aug 27, 2026 which is in 162 days.
How were MedAdvisor Limited’s earnings last quarter?
MedAdvisor Limited released its earnings results on Feb 26, 2026. The company reported AU$0.011 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.011.
Is MedAdvisor Limited overvalued?
According to Wall Street analysts MedAdvisor Limited’s price is currently Undervalued.
Does MedAdvisor Limited pay dividends?
MedAdvisor Limited does not currently pay dividends.
What is MedAdvisor Limited’s EPS estimate?
MedAdvisor Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MedAdvisor Limited have?
MedAdvisor Limited has 636,978,100 shares outstanding.
What happened to MedAdvisor Limited’s price movement after its last earnings report?
MedAdvisor Limited reported an EPS of AU$0.011 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MedAdvisor Limited?
Currently, no hedge funds are holding shares in AU:AHE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MedAdvisor Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:AHE Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth AU$64.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.95%
12-Months-Change
Fundamentals
Return on Equity
-137.16%
Trailing 12-Months
Asset Growth
-72.24%
Trailing 12-Months
Company Description
MedAdvisor Limited
Adheris Health Limited, together with its subsidiaries, provides pharmacy-driven patient engagement solutions in Australia, the United States, and the United Kingdom. The company offers THRiV, an omni-channel platform which provides pharmacy-driven patient and pharmacist engagement solutions to improve medication management. The company was formerly known as MedAdvisor Limited and changed its anme to Adheris Health Limited in November 2025. The company was incorporated in 2010 and is based in Woburn, Massachusetts.